Consensus and disputes on the adjuvant therapy for non-small cell lung cancer with positive surgical margins
Yuan Meng1, Men Yu2, Kang Jingjing1, Sun Xin1, Zhao Maoyuan1, Yang Xu1, Bao Yongxing1, Hui Zhouguang2
1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; 2Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract：For non-small cell lung cancer (NSCLC) patients with positive surgical margins, the survival rates can be dramatically decreased. However, high-level evidence is lacking in the standard adjuvant treatment for NSCLC patients with positive surgical margins. In this article, consensus and disputes on the adjuvant therapy for NSCLC patients with positive surgical margins were reviewed.
Yuan Meng,Men Yu,Kang Jingjing et al. Consensus and disputes on the adjuvant therapy for non-small cell lung cancer with positive surgical margins[J]. Chinese Journal of Radiation Oncology, 2020, 29(10): 904-908.
[1] Hancock JG, Rosen JE, Antonicelli A, et al. Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery[J]. Ann Thorac Surg, 2015, 99(2):406-413. DOI:10.1016/j.athoracsur.2014.09.033.
[2] Wind J, Smit EJ, Senan S, et al. Residual disease at the bronchial stump after curative resection for lung cancer[J]. Eur J Cardiothorac Surg, 2007, 32(1):29-34. DOI:10.1016/j.ejcts.2007.04.003.
[3] Riquet M, Achour K, Foucault C, et al. Microscopic residual disease after resection for lung cancer:a multifaceted but poor factor of prognosis[J]. Ann Thorac Surg, 2010, 89(3):870-875. DOI:10.1016/j.athoracsur.2009.11.052.
[4] Ohguri T, Yahara K, Moon SD, et al. Postoperative radiotherapy for incompletely resected nonsmall cell lung cancer:Clinical outcomes and prognostic value of the histological subtype[J]. J Radiat Res, 2012(53):319-325. DOI:10.1269/jrr.11082.
[5] Osarogiagbon RU, Lin CC, Smeltzer MP, et al. Prevalence, prognostic implications, and survival modulators of incompletely resected non-small cell lung cancer in the U. S. National Cancer Data Base[J]. J Thorac Oncol, 2016, 11(1):e5-16. DOI:10.1016/j.jtho.2015.08.002.
[6] 邓勇军, 杨鸿生, 施云飞, 等. 肺癌术后支气管切缘癌发生的相关因素分析[J]. 实用癌症杂志, 2003, 18(6):627-629. DOI:10.3969/j.issn.1001-5930.2003.06.024.
Deng YJ, Yang HS, Shi YF, et al. Risk factors for the residual carcinoma on the bronchial margin after radical resection of lung cancer[J]. Practic J Cancer, 2003, 18(6):627-629. DOI:10.3969/j.issn.1001-5930.2003.06.024.
[7] Snijder RJ, Brutel de la Rivière A, Elbers HJ, et al. Survival in resected stage Ⅰ lung cancer with residual tumor at the bronchial resection margin[J]. Ann Thorac Surg, 1998, 65(1):212-216. DOI:10.1016/s0003-4975(97)01114-4.
[8] Ghiribelli C, Voltolini L, Paladini P, et al. Treatment and survival after lung resection for non-small cell lung cancer in patients with microscopic residual disease at the bronchial stump[J]. Eur J Cardiothorac Surg, 1999, 16(5):555-559. DOI:10.1016/S1010-7940%2899%2900310-3.
[9] Hofmann HS, Taege C, Lautenschläger C, et al. Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer[J]. Eur J Cardiothorac Surg, 2002, 21(4):606-610. DOI:10.1016/S1010-7940(02)00030-1.
[10] Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients[J]. Ann Thorac Surg, 2005, 80(6):2051-2056. DOI:10.1016/j.athoracsur.2005.06.071.
[11] Lyu J, Hao X, Hui Z, et al. Prognosis of R1-resection at the bronchial stump in patients with non-small cell lung cancer[J]. Chin Med J (Engl), 2014, 127(16):2918-2923. DOI:10.3760/cma.j.issn.0366-6999.20140980.
[12] Smeltzer MP, Lin CC, Kong FS, et al. Survival impact of postoperative therapy modalities according to margin status in non-small cell lung cancer patients in the United States[J]. J Thorac Cardiovasc Surg, 2017, 154(2):661-672 e10. DOI:10.1016/j.jtcvs.2017.03.085.
[13] 陈跃军, 欧阳立志, 肖高明, 等. 肺癌术后支气管切缘癌阳性 40例临床分析[J]. 医学临床研究, 2004, 21(8):914-915. DOI:10.3969/j.issn.1671-7171.2004.08.033.
Chen YJ, Ouyang LZ, Xiao GM, et al. Clinical analysis of 40 cases of positive bronchial margin after lung cancer surgery[J]. J Clin Res, 2004, 21(8):914-915. DOI:10.3969/j.issn.1671-7171.2004.08.033.
[14] Ohguri T, Yahara K, Moon SD, et al. Postoperative radiotherapy for incompletely resected non-small cell lung cancer:clinical outcomes and prognostic value of the histological subtype[J]. J Radiat Res, 2012, 53(2):319-325. DOI:10.1269/jrr.11082.
[15] 胡小波, 王研, 崔有斌, 等. 非小细胞肺癌术后支气管切缘癌对预后的影响[J]. 吉林医学, 2005, 26(12):1282-1284. DOI:10.3969/j.issn.1004-0412.2005.12.012.
Hu XB, Wang Y, Cui YB, et al. Study of residual tumor on the bronchial margin after resection for non-small cell carcinoma of the lung[J]. Jilin Medical J, 2005, 26(12):1282-1284. DOI:10.3969/j.issn.1004-0412.2005.12.012.
[16] 卢喜科, 王嵩, 田铁栓. 非小细胞肺癌术后支气管切缘癌与预后[J]. 中华胸心血管外科杂志, 1998, 14(3):158-160. DOI:10.3760/cma.j.issn.1001-4497.1998.03.010.
Lu XK, Wang S, Tian TS. Study of residual tumor on the bronchial margin after resection for non-small cell carcinoma of the lung[J]. Chin J Thorac Cardiovasc Surg, 1998, 14(3):158-160. DOI:10.3760/cma.j.issn.1001-4497.1998.03.010.
[17] 王圆,王长利,岳东升. 支气管残端阳性非小细胞肺癌的预后分析[J]. 实用癌症杂志, 2009, 24(2):153-155,161. DOI:10.3969/j.issn.1001-5930.2009.02.014.
Wang Y, Wang CL, Yue DL. Prognostic analyses of non-small cell lung cancer with residual disease at the bronchial resection margin[J]. Practic J Cancer, 2009, 24(2):153-155,161. DOI:10.3969/j.issn.1001-5930.2009.02.014.
[18] 吴一龙, 黄植蕃, 戎铁华, 等. 非小细胞肺癌术后支气管残端阳性对预后的影响[J]. 肿瘤, 1997(4):16-18.
Wu YL, Huang ZF, Rong TH, et al. Influence of cancer residue in bronchial stump on the prognosis of non-small cell lung cancer patients[J]. Tumor, 1997(4):16-18.
[19] 马千里, 刘德若, 郭永庆, 等. 非小细胞肺癌袖式肺叶切除后切缘阳性的意义[J]. 中日友好医院学报, 2015, 29(3):135-138. DOI:10.3969/j.issn.1001-0025.2015.03.002.
Ma QL, Liu RD, Guo YQ, et al. Significance of the positive residual disease for non-small cell lung cancer after bronchial sleeve resection[J]. J China-Japan Friendship Hospital, 2015, 29(3):135-138. DOI:10.3969/j.issn.1001-0025.2015.03.002.
[20] 邓垒, 惠周光, 门玉, 等. 术前临床因素预测pⅢA-N2非小细胞肺癌术后放疗获益人群的研究[J]. 国际放射医学核医学杂志, 2018, 42(3):224-232. DOI:10.3760/cma.j.issn.1673-4114.2018.03.006.
Deng L, Hui ZG, Men Y, et al. Preoperative clinical risk factors in selecting patients with pathological ⅢA-N2 non-small-cell lung cancer benefiting from postoperative radiotherapy[J]. Int J Radiat Med Nucl Med, 2018, 42(3):224-232. DOI:10.3760/cma.j.issn.1673-4114.2018.03.006.
[21] Wang EH, Corso C, Rutter CE, et al. Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage Ⅱ and Ⅲ non-small-cell lung cancer[J]. J Clin Oncol, 2015, 33(25):2727-2734. DOI:10.1016/j.ijrobp.2015.07.1538.
[22] Rieber J, Alexander D, Elena U, et al. Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC)[J]. Lung Cancer, 2016, 91:41-47. DOI:10.1016/j.lungcan.2015.11.014.
[23] Lee GD, Kim DK, Jang SJ, et al. Significance of R1-resection at the bronchial margin after surgery for non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2017, 51(1):176-181. DOI:10.1093/ejcts/ezw242.
[24] Park J, Song S, Kim S, et al. Postoperative radiation therapy following the incomplete resection of a non-small cell lung cancer[J]. Radiat Oncol J, 2014, 32(2):70-76. DOI:10.3857/roj.2014.32.2.70.
[25] Zhou M, Li T, Liu Y, et al. Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer[J]. BMC Cancer, 2015, 15:36. DOI:10.1186/s12885-015-1036-0.
[26] Hui Z, Dai H, Liang J, et al. Selection of proper candidates with resected pathological stage ⅢA-N2 non-small cell lung cancer for postoperative radiotherapy[J]. Thorac Cancer, 2015, 6(3):346-353. DOI:10.1111/1759-7714.12186.
[27] Corso CD, Rutter CE, Wilson LD, et al. Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database[J]. J Thorac Oncol, 2015, 10(1):148-155. DOI:10.1097/JTO.0000000000000406.
[28] Douillard JY, Rosell R, Lena MD, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage Ⅰ, Ⅱ, or ⅢA non-small-cell lung cancer treated with adjuvant chemotherapy:the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial[J]. Int J Radiat Oncol Biol Phys, 2008, 72(3):695-701. DOI:10.1016/j.ijrobp.2008.01.044.
[29] Maygarden SJ, Detterbeck FC, Funkhouser WK. Bronchial margins in lung cancer resection specimens:utility of frozen section and gross evaluation[J]. Mod Pathol, 2004, 17(9):1080-1086. DOI:10.1038/modpathol.3800154.
[30] Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage ⅠB non-small-cell lung cancer:CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups[J]. J Clin Oncol, 2008(26):5043–5051. DOI:10.1200/JCO.2008.16.4855.
[31] Ghiribelli C, Voltolini L, Paladini P, et al. Treatment and survival after lung resection for nonsmall cell lung cancer in patients with microscopic residual disease at the bronchial stump[J]. Eur J Cardiothorac Surg, 1999, 16(5):555–559. DOI:10.1016/S1010-7940%2899%2900310-3.
[32] Hofmann HS, Taege C, Lautenschläger C, et al. Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer[J]. Eur J Cardiothorac Surg, 2002, 21(4):606-610. DOI:10.1016/S1010-7940(02)00030-1.
[33] Balasubramanian S, Au J, Dunning J. Should lobectomy patients with microscopic involvement of the bronchial resection margin undergo re-operation to improve their long-term survival?[J]. Interact Cardiovasc Thorac Surg, 2005, 4(6):531-537. DOI:10.1510/icvts.2005.114702.
[34] Francis S, Orton A, Stoddard G, et al. Sequencing of postoperative radiotherapy and chemotherapy for locally advanced or incompletely resected non–small-cell lung cancer[J]. J Clin Oncol, 2018, 36(4):333-341. DOI:10.1200/jco.2017.74.4771.
[35] Smeltzer MP, Lin CC, Kong FS, et al. Survival impact of post-operative therapy modalities after incomplete and complete surgical resection for non-small cell lung cancer in the US[C]// 16th World Conference on Lung Cancer. Denver, 2015.
2020, Vol. 29 
